The NeuroAiD II (MLC901) in Vascular Cognitive Impairment Study (NEURITES)

Background: A substantial proportion of patients after nondisabling stroke are cognitively impaired compared to age- and education-matched community-dwelling controls. Moreover, poststroke patients who have ‘vascular cognitive impairment no dementia' (VCIND) of moderate severity have a high ris...

Full description

Saved in:
Bibliographic Details
Main Authors: Chen, Christopher L.H., Ikram, Kamran, Anqi, Qiu, Yin, Wong Tien, Venketasubramanian, Narayanaswamy, Chen, Annabel Shen-Hsing
Other Authors: School of Humanities and Social Sciences
Format: Article
Language:English
Published: 2017
Subjects:
Online Access:https://hdl.handle.net/10356/85129
http://hdl.handle.net/10220/43643
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Nanyang Technological University
Language: English
id sg-ntu-dr.10356-85129
record_format dspace
spelling sg-ntu-dr.10356-851292020-03-07T12:10:38Z The NeuroAiD II (MLC901) in Vascular Cognitive Impairment Study (NEURITES) Chen, Christopher L.H. Ikram, Kamran Anqi, Qiu Yin, Wong Tien Venketasubramanian, Narayanaswamy Chen, Annabel Shen-Hsing School of Humanities and Social Sciences Stroke Cognitive impairment Neuroplasticity Neuroprotection Background: A substantial proportion of patients after nondisabling stroke are cognitively impaired compared to age- and education-matched community-dwelling controls. Moreover, poststroke patients who have ‘vascular cognitive impairment no dementia' (VCIND) of moderate severity have a high risk of incident dementia, dependency and death. Further studies are urgently needed to demonstrate effective cognition-enhancing therapies in VCIND given the scarcity of evidence-based treatment options. NeuroAiD is a traditional Chinese medicine that has been shown to induce neuroplasticity, promote cell proliferation and stimulate the development of dense axonal and dendritic networks in animal stroke models. NeuroAiD may improve cerebral blood flow and functional recovery after stroke in patients. Objective: To investigate the effects and tolerability of NeuroAiD II in patients with VCIND. Methods: The NeuroAiD II (MLC901) in Vascular Cognitive Impairment Study (NEURITES) is a 24-week, double-blind, randomized, placebo-controlled phase II study of NeuroAiD II in patients with VCIND. The primary outcome is executive function as measured by the Verbal Fluency test. Secondary outcomes include cognitive assessments such as the ADAS-Cog, MoCA, MMSE and Cognitive Battery: activities of daily living as measured by the Alzhei-mer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) scale for mild cognitive impairment, behavior as measured by the Neuropsychiatric Inventory, and depression as measured by the Geriatric Depression Scale and the Beck Depression Scale. In addition, there will be novel exploratory outcomes: (a) magnetic resonance imaging of lesion location (structural imaging), structural integrity of white matter pathways (diffusion tensor imaging), neuronal function (resting studies) and perfusion (arterial spin labeling and MR angiography), and (b) retinal and optic nerve imaging. Safety and tolerability will be assessed using adverse events, laboratory tests and vital signs. Conclusions: NEURITES has the potential to set new standards for the systematic evaluation of Asian traditional medicine for integration into standard medicine practice and establishing a novel therapeutic approach for improving cognition after stroke. Published version 2017-08-29T01:44:25Z 2019-12-06T15:57:40Z 2017-08-29T01:44:25Z 2019-12-06T15:57:40Z 2013 Journal Article Chen, C. L., Ikram, K., Anqi, Q., Yin, W. T., Chen, A., & Venketasubramanian, N. (2013). The NeuroAiD II (MLC901) in Vascular Cognitive Impairment Study (NEURITES). Cerebrovascular Diseases, 35(s1), 23-29. 1015-9770 https://hdl.handle.net/10356/85129 http://hdl.handle.net/10220/43643 10.1159/000346234 en Cerebrovascular Diseases © 2013 S. Karger AG, Basel. Th is is an Open Access article licensed under the terms of the Creative Commons Attribution NonCommercial-No-Derivs 3.0 License (www.karger.com/OA-license), applicable to the online version of the article only. Distribution for non-commercial purposes only. 7 pg. application/pdf
institution Nanyang Technological University
building NTU Library
country Singapore
collection DR-NTU
language English
topic Stroke
Cognitive impairment
Neuroplasticity
Neuroprotection
spellingShingle Stroke
Cognitive impairment
Neuroplasticity
Neuroprotection
Chen, Christopher L.H.
Ikram, Kamran
Anqi, Qiu
Yin, Wong Tien
Venketasubramanian, Narayanaswamy
Chen, Annabel Shen-Hsing
The NeuroAiD II (MLC901) in Vascular Cognitive Impairment Study (NEURITES)
description Background: A substantial proportion of patients after nondisabling stroke are cognitively impaired compared to age- and education-matched community-dwelling controls. Moreover, poststroke patients who have ‘vascular cognitive impairment no dementia' (VCIND) of moderate severity have a high risk of incident dementia, dependency and death. Further studies are urgently needed to demonstrate effective cognition-enhancing therapies in VCIND given the scarcity of evidence-based treatment options. NeuroAiD is a traditional Chinese medicine that has been shown to induce neuroplasticity, promote cell proliferation and stimulate the development of dense axonal and dendritic networks in animal stroke models. NeuroAiD may improve cerebral blood flow and functional recovery after stroke in patients. Objective: To investigate the effects and tolerability of NeuroAiD II in patients with VCIND. Methods: The NeuroAiD II (MLC901) in Vascular Cognitive Impairment Study (NEURITES) is a 24-week, double-blind, randomized, placebo-controlled phase II study of NeuroAiD II in patients with VCIND. The primary outcome is executive function as measured by the Verbal Fluency test. Secondary outcomes include cognitive assessments such as the ADAS-Cog, MoCA, MMSE and Cognitive Battery: activities of daily living as measured by the Alzhei-mer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) scale for mild cognitive impairment, behavior as measured by the Neuropsychiatric Inventory, and depression as measured by the Geriatric Depression Scale and the Beck Depression Scale. In addition, there will be novel exploratory outcomes: (a) magnetic resonance imaging of lesion location (structural imaging), structural integrity of white matter pathways (diffusion tensor imaging), neuronal function (resting studies) and perfusion (arterial spin labeling and MR angiography), and (b) retinal and optic nerve imaging. Safety and tolerability will be assessed using adverse events, laboratory tests and vital signs. Conclusions: NEURITES has the potential to set new standards for the systematic evaluation of Asian traditional medicine for integration into standard medicine practice and establishing a novel therapeutic approach for improving cognition after stroke.
author2 School of Humanities and Social Sciences
author_facet School of Humanities and Social Sciences
Chen, Christopher L.H.
Ikram, Kamran
Anqi, Qiu
Yin, Wong Tien
Venketasubramanian, Narayanaswamy
Chen, Annabel Shen-Hsing
format Article
author Chen, Christopher L.H.
Ikram, Kamran
Anqi, Qiu
Yin, Wong Tien
Venketasubramanian, Narayanaswamy
Chen, Annabel Shen-Hsing
author_sort Chen, Christopher L.H.
title The NeuroAiD II (MLC901) in Vascular Cognitive Impairment Study (NEURITES)
title_short The NeuroAiD II (MLC901) in Vascular Cognitive Impairment Study (NEURITES)
title_full The NeuroAiD II (MLC901) in Vascular Cognitive Impairment Study (NEURITES)
title_fullStr The NeuroAiD II (MLC901) in Vascular Cognitive Impairment Study (NEURITES)
title_full_unstemmed The NeuroAiD II (MLC901) in Vascular Cognitive Impairment Study (NEURITES)
title_sort neuroaid ii (mlc901) in vascular cognitive impairment study (neurites)
publishDate 2017
url https://hdl.handle.net/10356/85129
http://hdl.handle.net/10220/43643
_version_ 1681037236880015360